Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vanoxerine for recent-onset atrial fibrillation or atrial flutter conversion
NL-OMON42537Phase 3Active, not recruiting
- Sponsor
- Laguna Pharmaceuticals, Inc
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) and atrial flutter (AFL) comparing Vanoxerine with Placebo (2 arms). Primary endpoints: Conversion to sinus rhythm within 24 hours, Death through Day 8 and 4 more. Started Nov 2015; status: active, not recruiting.
02
Drugs
vanoxerine
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NL-OMON42537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42537.